Results 151 to 160 of about 4,569 (190)
, 2015 Some of the next articles are maybe not open access.
Related searches:
Related searches:
Radium-223 for the treatment of prostate cancer
Expert Opinion on Investigational Drugs, 2013Bone metastases cause significant morbidity and mortality in castration-resistant prostate cancer (CRPC). Until recently, treatment options have been limited, but now six drugs are known to extend life expectancy, with docetaxel the current standard first-line cytotoxic therapy.
Shaista, Hafeez, Christopher, Parker
openaire +2 more sources
Alphastrahler Radium-223-Dichlorid
Der Urologe, 2014Radium-223 dichloride (Ra-223) is an alpha emitter with low toxicity for the treatment of patients with castrations-resistant prostate cancer (CRPC) and symptomatic bone metastases showing a 30% reduction in the risk of death, as compared to placebo. Because of the favorable physical and chemical characteristics, Ra-223 can be handled easily in daily ...
H. Heinzer, F. König, S. Klutmann
openaire +1 more source
Journal of Inorganic and Nuclear Chemistry, 1965
Abstract The half-life of radium-223 has been determined simultaneously by microcalorimetry and proportional alpha counting, with 5 mc of radium-223 separated from actinium-227 and thorium-227 by cation exchange. A 4-mc fraction of the purified radium-223 was transferred to a tantalum capsule, dried, ignited at red heat, and hermetically sealed. The
H.W. Kirby +4 more
openaire +1 more source
Abstract The half-life of radium-223 has been determined simultaneously by microcalorimetry and proportional alpha counting, with 5 mc of radium-223 separated from actinium-227 and thorium-227 by cation exchange. A 4-mc fraction of the purified radium-223 was transferred to a tantalum capsule, dried, ignited at red heat, and hermetically sealed. The
H.W. Kirby +4 more
openaire +1 more source
Assessing therapeutic response to Radium-223
Seminars in Nuclear MedicineRadium-223 (223Ra), an alpha-emitting radiopharmaceutical targets bone and prolongs overall survival (OS) while reducing skeletal-related events (SREs) in metastatic castration-resistant prostate cancer patients (mCRPC). However, assessing 223Ra therapeutic response is difficult due to its distinct mechanism of action on bone remodeling and tumor ...
Caroline Torricelli +2 more
openaire +2 more sources